CannabisNewsBreaks Archive - Page 37 of 429

ThursdayNov 03, 2022 1:07 pm

CannabisNewsBreaks – Advanced Container Technologies Inc. (ACTX) Offer Options for Farmers Looking to Meet Changing Food Demands

Advanced Container Technologies (OTC: ACTX), the exclusive U.S. distributor of self-contained, automated, indoor “micro-farms” called GrowPods, offer numerous benefits for farmers looking to be dynamic and fluid. GrowPods are unique controlled environment farms that don’t use expensive, dangerous pesticides and herbicides and provide a way for farmers to identify crops that are in short supply and then grow those crops, quickly and efficiently. A recent CNBC report noted that there is currently a “massive strain on global food supply,” especially as the world recovers from the global pandemic. That need, combined with the increasing costs of fertilizer and pesticides, make…

WednesdayNov 02, 2022 2:11 pm

CannabisNewsBreaks – Advanced Container Technologies Inc. (ACTX) Enabling States to be Agriculture Independent, Grow Food Year-Round

Advanced Container Technologies (OTC: ACTX) is dedicated to developing, manufacturing and selling advanced cultivation equipment, proprietary packaging systems, and a variety of other products. “One of the company’s main business units is focused on selling Grow Pods, which are advanced, self-contained hydroponic containers. These innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with a controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year,” a recent article reads. “The good thing about the [Grow Pods] container is that it can give traditional farmers a niche where they can…

TuesdayNov 01, 2022 1:26 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures IRB Approval for Human Clinical Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of independent review board (“IRB”) approval for human clinical nicotine study NIC-H22-1, and that human dosing will begin soon. The 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study will be conducted in current cigarette smokers, wherein each person will visit the laboratory to be dosed three times over a period of weeks. Only one oral nicotine pouch (either DehydraTECH-nicotine; On! brand manufactured by Altria; or Zyn brand manufactured by Swedish Match) will be administered during each visit and evaluated. Predetermined questionnaires for subjective…

FridayOct 28, 2022 11:58 am

CannabisNewsBreaks – REZYFi Inc. Ideally Poised amid Potential Shifts in Marijuana Jurisprudence

REZYFi, a growth mortgage origination and specialized financing company focused on the cannabis industry, is positioned to benefit from recent efforts in the U.S. with respect to marijuana. “In what pundits describe as a move to follow through on some of his campaign promises, the President announced a blanket federal pardon for people incarcerated for marijuana possession. Biden also tasked the Health Secretary and Attorney General with initiating a process that could culminate in the rescheduling of marijuana, which is currently classified as a Schedule 1 drug, a category supposedly meant for substances with a high potential for abuse and…

ThursdayOct 27, 2022 3:13 pm

CannabisNewsBreaks – Upcoming Tampa Event to Feature Cutting-Edge Offerings in the Alternative Products Space

On the heels of several successful events in North and South America, the Alternative Products Expo is set to arrive in Florida, at the Tampa Convention Center, on Nov. 10-12, 2022. The event will feature expert speakers, over 300 exhibitors, and more than 1,000 cutting-edge products in the exciting alternative products space. Renowned speakers will share their knowledge through keynotes, engaging panel discussions and specialized workshops. Attendees will have the opportunity to experience more than 250 vendors showcasing a significant array of goods and services while enjoying the festive atmosphere. “We're really excited about our first Tampa show, as this…

ThursdayOct 27, 2022 1:26 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Successful Results of Human Clinical Hypertension Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study, HYPER-H21-4, may be the first-ever study to indicate a sustained drop in blood pressure (“BP”) in normally active hypertensive patients following multiple weeks of oral cannabidiol ("CBD") therapy. The study is evaluating Lexaria's patented DehydraTECH(TM)-CBD capsule formulation. LEXX reported that study results showed exceptional safety and tolerability and statistically significant lowering of 24-hour ambulatory BP as well as BP lowered for the duration of the entire five-week study. The study also indicated lowered BP for patients currently taking other antihypertensive drugs as well…

WednesdayOct 26, 2022 11:23 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Support of EB Awareness Week

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, today announced that it is supporting initiatives to raise awareness of epidermolysis bullosa, a group of rare genetic connective tissue disorders. Epidermolysis Bullosa Global Awareness Week is Oct. 25-31, 2022. “In severe cases of epidermolysis bullosa, or EB, the very fragile skin tears easily and forms painful blisters and open wounds that do not heal quickly,” said Alexandra Mancini, SVP of Clinical and Regulatory Affairs for InMed. “EB is a very important but rare disease that does not get the attention it deserves. EB Awareness…

TuesdayOct 25, 2022 10:50 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces Webcast to Discuss M&A, International Markets

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has scheduled an analyst call for Oct. 26, 2022, at 2 p.m. EST. According to the announcement, the call will focus on the company’s recent M&A activity as well as growth opportunities in the international space. Leadership from Flora Growth, along with Franchise Global Health Inc., will be on the call to discuss the recent definitive agreement that two companies have signed regarding acquisition; discussion will also center on global opportunities within the cannabis industry. Through its subsidiaries, Franchise Global Health is a multinational…

MondayOct 24, 2022 10:29 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Enters into Acquisition Agreement with German-Based Pharmaceutical, Medical Cannabis Distributor

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has inked a definitive agreement with Franchise Global Health Inc. (TSX.V: FGH), a multinational operator in the medical cannabis and pharmaceutical industry. The agreement outlines Flora Growth’s plans to acquire 100% of Franchise Global Health, which has principal operations in Germany, in an all-stock transaction. According to the agreement, the acquisition gives FLGC a foothold in German’s medical cannabis space because FGH’s German businesses service an estimated 1,200 pharmacies in the country; FGH also provides noncannabis medical products to 28 additional countries. In the first…

FridayOct 21, 2022 3:21 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Holds Potential to Represent Multiple Commercial Opportunities

Lexaria Bioscience Corp. (NASDAQ: LEXX), a drug delivery platform innovator, last year announced a review of its successful 2021 antiviral drug program. “Lexaria specifically probed the bioavailability of five DehydraTECH(TM)-processed antiviral drugs for SARS-CoV-2, HIV/AIDS and other infectious diseases from three drug classes, evidencing significant gains with up to a three-fold increase in oral drug delivery into the bloodstream. The demonstrated improvements in absorption, Lexaria believed, could have significant commercial potential considering that many antiviral drugs typically show low oral bioavailability in their available form because of significant liver biotransformation and/or poor intestinal uptake,” reads a recent article. “Lexaria’s vision…

News and publishing service for cannabis related companies

Contact us: 512.354.7000

CannabisNewsBreaks